TL;DR: Curaleaf Holdings (CURLF: OTC) enters the final sessions before its August 5 earnings date with year-to-date gains of 22.7%, a one-year return of 158.5%, and trailing revenue of \$1.29 billion that makes it the largest U.S. multi-state operator by scale. As Monday’s cannabis tape closes on a constructive note — OGI +3%, Tilray pre-earnings setup in focus for Tuesday — Curaleaf’s Q2 2026 print is the next major catalyst for the sector, four sessions after Tilray’s Q4 FY2026 results open earnings season.
Market Analysis
Curaleaf’s OTC-listed shares last printed at \$9.46 on a session that marked a 1.72% daily gain, with a 52-week range of \$2.83 to \$15.15 framing the remarkable distance the stock has traveled since its trough. Year-to-date gains of 22.7% outpace the broader MSOS ETF’s 9.75% advance and reflect investor recognition that the company’s restructuring thesis — cost reduction at the store level, divestiture of underperforming markets, and a pivot toward free cash flow generation — is producing measurable results.
The numbers support the narrative. Revenue of \$1.29 billion on a trailing twelve-month basis places Curaleaf in rare company within the North American cannabis landscape. Levered free cash flow of \$82.49 million signals that operational cash generation has turned the corner, even as the income statement continues to reflect the weight of legacy debt service and non-cash charges. EPS of -\$0.42 TTM is the headline number, but it obscures a business that is generating real cash — a distinction the August 5 earnings call is expected to clarify.
Enterprise value sits at \$3.24 billion against an EV/EBITDA multiple of 14.31x — a valuation that prices in continued operational improvement but still leaves meaningful room for expansion if the company delivers a beat-and-raise on August 5. Analyst consensus has converged around a \$15.00 price target, implying 58.5% upside from the most recent close. Market cap of \$2.51 billion reflects the scale gap between Curaleaf and its MSO peers — Green Thumb, Trulieve, and TerrAscend all trade at materially smaller market caps.
On the balance sheet, total debt/equity runs at 114.54%, which remains an overhang, but levered free cash flow of \$82.49 million signals that operational fundamentals are improving faster than the income statement suggests. The August 5 earnings call is expected to provide updated guidance on both debt reduction progress and state-level revenue trajectory.
Regulatory and Market Context
Monday’s cannabis sector session reinforced the backdrop against which Curaleaf’s August print will be evaluated. Organigram (OGI) posted a 3% gain on strong volume, TerrAscend (TRSSF) provided detailed Q2 guidance anchored in Pennsylvania and New Jersey, and AYR Wellness (AYRWF) continued its Southeast-focused profitability narrative. Tilray Brands (TLRY) dominated the news cycle with its pre-earnings setup — Q4 FY2026 results are due Tuesday morning and represent the first major cannabis earnings print of the August reporting window.
The MSOS ETF, which holds Curaleaf’s Toronto-listed shares (CURA.TO) as its largest position at 12.18% of total assets, closed July 24 at \$4.26 before recovering to \$4.35 in after-hours trading — a 2.11% gain that suggests institutional positioning ahead of the earnings catalyst stack. With MSOS posting a 50% one-year return and the ETF’s holdings concentrated in the same MSO cohort that reports through August 12, earnings season volatility will be amplified for index-tracking products.
Federal regulatory developments remain a steady undercurrent. Schedule III rescheduling — still progressing through the DEA administrative review process — represents a material catalyst for Curaleaf specifically, given the company’s heavy 280E tax burden. Any forward guidance on the tax relief timeline will receive outsized attention on the August 5 call, as 280E normalization could add meaningfully to bottom-line EPS without requiring additional operational improvement.
Conclusion — Forward-Looking
Tuesday belongs to Tilray. But August 5 is Curaleaf’s date, and the setup heading in is as constructive as it has been in several quarters. With levered FCF positive, revenue leadership intact, and the stock still trading 37.5% below its 52-week high despite a 158.5% one-year run, the risk/reward into the print reflects a market that has begun to believe in the turnaround without yet fully pricing it. The key metrics to track: revenue trajectory by state, adjusted EBITDA margin progression, and any updated language on the federal reform timeline.
For live price and peer comparison data through tonight’s close, visit our cannabis stock tracker.